Bifunctional HER2-Targeted Sialidase (Palleon Pharmaceuticals)

N/A

Report date: 2024/02/22 17:56:53

Base Information

Drug NameBifunctional HER2-Targeted Sialidase (Palleon Pharmaceuticals)
Drug Alias NameHER2-SialidaseE-434HLX-314
ClassificationBiologics > Protein drugs > EnzymeCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsT lymphocytes stimulantsGlycoproteins modulators
TargetsReceptor protein-tyrosine kinase erbB-2Glycoproteins
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaPreclinical
Originator CompaniesPalleon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPalleon Pharmaceuticals IncShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A